Azher Hussain
Overview
Explore the profile of Azher Hussain including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
308
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yap T, Bullock J, Chong S, Doyle M, Hussain A, Kline J, et al.
Clin Cancer Res
. 2024 Oct;
30(23):5237-5241.
PMID: 39365679
The Project Optimus initiative from the FDA introduced a new dose optimization and selection paradigm in oncology drug development. The FDA has outlined approaches to dose optimization for single agents,...
2.
Arbelaez F, Joeng H, Hussain A, Sunga S, Guan Y, Chawla A, et al.
Fertil Steril
. 2024 Sep;
123(2):280-288.
PMID: 39260540
Objective: To evaluate the P2X3 receptor antagonist, gefapixant, for treating moderate-to-severe endometriosis-related pain. Design: Randomized, double-blind, phase 2, and proof-of-concept trial. Subjects: Premenopausal women age 18-49 years with moderate-to-severe endometriosis-related...
3.
Robbins J, Sands S, Maganti L, Crumley T, Fox-Bosetti S, Hussain A, et al.
J Clin Sleep Med
. 2024 Jul;
20(12):1905-1913.
PMID: 39069967
Study Objectives: Obstructive sleep apnea (OSA) is a highly prevalent disorder with serious health consequences but limited therapeutic options. For a subset of those with OSA, a key underlying mechanism...
4.
Samineni D, Venkatakrishnan K, Othman A, Pithavala Y, Poondru S, Patel C, et al.
Clin Pharmacol Ther
. 2024 May;
116(3):531-545.
PMID: 38752712
The landscape of oncology drug development has witnessed remarkable advancements over the last few decades, significantly improving clinical outcomes and quality of life for patients with cancer. Project Optimus, introduced...
5.
Nussbaum J, Hussain A, Butera P, Ford A, Kitt M, ONeill E, et al.
J Clin Pharmacol
. 2024 Apr;
64(8):1023-1029.
PMID: 38651193
Gefapixant (MK-7264, RO4926219, AF-219) is a first-in-class P2X3 antagonists being developed to treat refractory or unexplained chronic cough. The initial single- and multiple-dose safety, tolerability, and pharmacokinetics of gefapixant at...
6.
Chawla A, Largajolli A, Hussain A, Kleijn H, Ait-Oudhia S, Anton J, et al.
CPT Pharmacometrics Syst Pharmacol
. 2023 May;
12(8):1107-1118.
PMID: 37147897
Gefapixant, a P2X3-receptor antagonist, demonstrated objective and subjective efficacy in individuals with refractory or unexplained chronic cough. We report a population pharmacokinetic (PopPK) analysis that characterizes gefapixant pharmacokinetics (PKs), quantifies...
7.
Nussbaum J, Hussain A, Ford A, Butera P, Kitt M, Smith S, et al.
Lung
. 2022 Jun;
200(3):315-323.
PMID: 35670873
Purpose: Patients with chronic cough are typically female and have a mean age of ~ 60 years. However, initial pharmacokinetic (PK) characterization of the P2X3-receptor antagonist gefapixant, developed to treat...
8.
Nussbaum J, Hussain A, Min K, Marbury T, Lasseter K, Stoch S, et al.
J Clin Pharmacol
. 2022 Jun;
62(11):1435-1444.
PMID: 35656754
Gefapixant, a P2X3 receptor antagonist, has demonstrated efficacy in patients with refractory or unexplained chronic cough. We investigated the effect of renal impairment (RI) on the pharmacokinetics (PK) of gefapixant...
9.
Gupta P, Hussain A, Ford A, Smith S, Nussbaum J, Stoch A, et al.
Clin Pharmacol Drug Dev
. 2022 May;
11(9):1054-1067.
PMID: 35510785
Gefapixant is a P2X3-receptor antagonist being developed for treatment of refractory or unexplained chronic cough. Four phase 1 studies were conducted in healthy participants that bridged the early-phase gefapixant formulation...
10.
Nussbaum J, Hussain A, Ma B, Min K, Chen Q, Tomek C, et al.
Pharmacol Res Perspect
. 2022 Feb;
10(1):e00924.
PMID: 35106949
Gefapixant (MK-7264) is a first-in-class, selective antagonist of the P2X3 purinergic receptor currently being investigated as a therapeutic agent for the treatment of refractory or unexplained chronic cough. In non-clinical...